<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="srt70207" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Skin Res Technol</journal-id><journal-id journal-id-type="iso-abbrev">Skin Res Technol</journal-id><journal-id journal-id-type="pmc-domain-id">4358</journal-id><journal-id journal-id-type="pmc-domain">skinres</journal-id><journal-id journal-id-type="publisher-id">SRT</journal-id><journal-title-group><journal-title>Skin Research and Technology</journal-title></journal-title-group><issn pub-type="ppub">0909-752X</issn><issn pub-type="epub">1600-0846</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430830</article-id><article-id pub-id-type="pmcid-ver">PMC12430830.1</article-id><article-id pub-id-type="pmcaid">12430830</article-id><article-id pub-id-type="pmcaiid">12430830</article-id><article-id pub-id-type="pmid">40939092</article-id><article-id pub-id-type="doi">10.1111/srt.70207</article-id><article-id pub-id-type="publisher-id">SRT70207</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Discovery of a Novel Cyclopeptide as Tyrosinase Inhibitor for Skin Lightening</article-title></title-group><contrib-group><contrib id="srt70207-cr-0001" contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="H">Huailong</given-names></name><xref rid="srt70207-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="srt70207-cr-0002" contrib-type="author"><name name-style="western"><surname>Tao</surname><given-names initials="K">Kan</given-names></name><xref rid="srt70207-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="srt70207-cr-0003" contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="H">Hu</given-names></name><xref rid="srt70207-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="srt70207-cr-0004" contrib-type="author"><name name-style="western"><surname>Jia</surname><given-names initials="J">Jinping</given-names></name><xref rid="srt70207-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="srt70207-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Khan</surname><given-names initials="SN">Shah Nawaz</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3052-3510</contrib-id><xref rid="srt70207-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="srt70207-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>SnKhan@sjtu.edu.cn</email></address></contrib><contrib id="srt70207-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Cui</surname><given-names initials="J">Jiahua</given-names></name><xref rid="srt70207-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>cpucjh@sjtu.edu.cn</email></address></contrib></contrib-group><aff id="srt70207-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Global R&amp;D Center</named-content>
<institution>Shanghai Chicmax Cosmetic Co. Ltd</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="srt70207-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Chemistry and Chemical Engineering</named-content>
<institution>Shanghai Jiaotong University</institution>
<city>Shanghai</city>
<country country="CN">China</country>
</aff><aff id="srt70207-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacy</named-content>
<institution>University of Malakand</institution>
<city>Khyber Pakhtunkhwa</city>
<country country="PK">Pakistan</country>
</aff><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>31</volume><issue seq="50">9</issue><issue-id pub-id-type="pmc-issue-id">496744</issue-id><issue-id pub-id-type="doi">10.1111/srt.v31.9</issue-id><elocation-id>e70207</elocation-id><history><date date-type="rev-recd"><day>02</day><month>5</month><year>2025</year></date><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Skin Research and Technology</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="SRT-31-e70207.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:SRT-31-e70207.pdf"/><abstract><title>ABSTRACT</title><sec id="srt70207-sec-0010"><title>Background</title><p>Melanin synthesis plays a crucial role in skin pigmentation, and inhibiting tyrosinase, the key enzyme in melanin production, is a primary strategy for developing skin&#8208;lightening agents. This study investigates the tyrosinase inhibitory potential of <bold>CHP&#8208;9</bold>, a novel cyclopeptide, and evaluates its cytotoxicity and efficacy as a cosmetic depigmenting agent.</p></sec><sec id="srt70207-sec-0020"><title>Methods</title><p>
<bold>CHP&#8208;9</bold> was synthesized via a solid&#8208;phase peptide synthesis strategy. The tyrosinase inhibitory activity was assessed using an enzymatic assay, while its effects on melanin content were evaluated in cultured human melanocytes. The MTT assay was performed to assess cytotoxicity across a range of <bold>CHP&#8208;9</bold> concentrations (0.0781&#8211;10&#160;mg/mL). Molecular docking simulations were conducted to elucidate the interaction between <bold>CHP&#8208;9</bold> and human tyrosinase (PDB ID: 5M8M). Statistical analysis was performed using GraphPad Prism Software, and significance was determined via one&#8208;way ANOVA.</p></sec><sec id="srt70207-sec-0030"><title>Results</title><p>
<bold>CHP&#8208;9</bold> exhibited significant tyrosinase inhibition (28.57% at 1% concentration) and reduced melanin content in treated melanocytes from 30.90 &#177; 1.13 to 23.51 &#177; 1.14&#160;&#181;g/mL. Cytotoxicity assays confirmed CHP&#8208;9's high biocompatibility, with cell viability exceeding 90% at concentrations up to 2.5&#160;mg/mL. Docking studies revealed strong binding affinity between <bold>CHP&#8208;9</bold> and key tyrosinase residues via hydrogen bonding, supporting its inhibitory mechanism.</p></sec><sec id="srt70207-sec-0040"><title>Conclusions</title><p>
<bold>CHP&#8208;9</bold> exhibited significant tyrosinase inhibition (28.57% at 1% concentration) and reduced melanin content in melanocytes, while maintaining over 90% cell viability at effective doses. These findings suggest that CHP&#8208;9 is a safe and effective candidate for cosmetic skin&#8208;lightening applications. Further research is needed to enhance formulation stability and evaluate long&#8208;term efficacy in vivo.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="srt70207-kwd-0001">chemical synthesis</kwd><kwd id="srt70207-kwd-0002">cosmetics</kwd><kwd id="srt70207-kwd-0003">cyclopeptide</kwd><kwd id="srt70207-kwd-0004">molecular docking</kwd><kwd id="srt70207-kwd-0005">skin lightening</kwd><kwd id="srt70207-kwd-0006">tyrosinase inhibitors</kwd></kwd-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="8"/><word-count count="4633"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:12.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="srt70207-cit-0001"><string-name name-style="western"><given-names>H.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tao</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Khan</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Cui</surname></string-name>, &#8220;<article-title>Discovery of a Novel Cyclopeptide as Tyrosinase Inhibitor for Skin Lightening</article-title>.&#8221; <source>Skin Research and Technology</source><volume>31</volume>, no. <issue>9</issue> (<year>2025</year>): <elocation-id>e70207</elocation-id>. <pub-id pub-id-type="doi">10.1111/srt.70207</pub-id><pub-id pub-id-type="pmcid">PMC12430830</pub-id><pub-id pub-id-type="pmid">40939092</pub-id></mixed-citation>
</p></notes></front><body><sec id="srt70207-sec-0050"><label>1</label><title>Introduction</title><p>Hyperpigmentation is a prevalent cosmetic concern characterized by excessive melanin deposition in sun&#8208;exposed skin regions due to heightened melanogenesis [<xref rid="srt70207-bib-0001" ref-type="bibr">1</xref>]. While naturally sun&#8208;induced melanin production offers photoprotective benefits and contributes to a natural tan, localized overaccumulation of melanin often results in undesirable dark spots, posing significant cosmetic challenges [<xref rid="srt70207-bib-0002" ref-type="bibr">2</xref>, <xref rid="srt70207-bib-0003" ref-type="bibr">3</xref>].</p><p>Tyrosinase is a key enzyme in the polyphenol oxidase family and serves as the central catalyst in melanin biosynthesis [<xref rid="srt70207-bib-0004" ref-type="bibr">4</xref>, <xref rid="srt70207-bib-0005" ref-type="bibr">5</xref>, <xref rid="srt70207-bib-0006" ref-type="bibr">6</xref>, <xref rid="srt70207-bib-0007" ref-type="bibr">7</xref>] by converting tyrosine into L&#8208;DOPA and subsequently oxidizing L&#8208;DOPA to O&#8208;quinone, which undergoes spontaneous reactions to synthesize melanin [<xref rid="srt70207-bib-0008" ref-type="bibr">8</xref>, <xref rid="srt70207-bib-0009" ref-type="bibr">9</xref>]. Overproduction of melanin driven by tyrosinase hyperactivity is directly linked to hyperpigmentation disorders such as solar lentigo, chloasma, and freckles, which can markedly alter phenotypic appearance [<xref rid="srt70207-bib-0010" ref-type="bibr">10</xref>]. Beyond its role in skin pigmentation, dysregulated tyrosinase activity plays a crucial role in neurodegenerative conditions like Parkinson's and Alzheimer's diseases [<xref rid="srt70207-bib-0011" ref-type="bibr">11</xref>, <xref rid="srt70207-bib-0012" ref-type="bibr">12</xref>] and food science [<xref rid="srt70207-bib-0013" ref-type="bibr">13</xref>, <xref rid="srt70207-bib-0014" ref-type="bibr">14</xref>]. Given these implications, targeted inhibition of tyrosinase's catalytic activity emerges as a promising strategy for mitigating hyperpigmentation (e.g., skin lightening) and addressing other conditions as well.</p><p>The readily available ascorbic acid [<xref rid="srt70207-bib-0015" ref-type="bibr">15</xref>, <xref rid="srt70207-bib-0016" ref-type="bibr">16</xref>], kojic acid [<xref rid="srt70207-bib-0017" ref-type="bibr">17</xref>], arbutin [<xref rid="srt70207-bib-0018" ref-type="bibr">18</xref>, <xref rid="srt70207-bib-0019" ref-type="bibr">19</xref>], and hydroquinone [<xref rid="srt70207-bib-0020" ref-type="bibr">20</xref>, <xref rid="srt70207-bib-0021" ref-type="bibr">21</xref>, <xref rid="srt70207-bib-0022" ref-type="bibr">22</xref>] are among the myriad of tyrosinase inhibitors. Nonetheless, the drawbacks of these inhibitors make them blemished due to the potential carcinogenicity, high cellular toxicity, instability, and off&#8208;odor propensities [<xref rid="srt70207-bib-0022" ref-type="bibr">22</xref>, <xref rid="srt70207-bib-0023" ref-type="bibr">23</xref>, <xref rid="srt70207-bib-0024" ref-type="bibr">24</xref>]. With the growing consumer awareness toward the possible side effects of these inhibitors, there is a high demand for naturally occurring tyrosinase inhibitors as a safer alternative.</p><p>Bioactive peptides derived from food have emerged as promising alternatives due to their potential effectiveness, availability, targeting capabilities, safety, and specificity [<xref rid="srt70207-bib-0025" ref-type="bibr">25</xref>, <xref rid="srt70207-bib-0026" ref-type="bibr">26</xref>]. However, despite the potential theoretical and practical application of these peptides, they always encounter challenges, along with their stability and selectivity, which remain a critical concern for peptide tyrosinase inhibitors [<xref rid="srt70207-bib-0025" ref-type="bibr">25</xref>, <xref rid="srt70207-bib-0027" ref-type="bibr">27</xref>, <xref rid="srt70207-bib-0028" ref-type="bibr">28</xref>]. These limitations are evident in both in vivo and in vitro environments, where many peptide compounds undergo rapid deactivation. This instability reduces their ability to provide sustained effects, ultimately compromising therapeutic efficacy and the overall patient experience. Furthermore, the bioavailability of these inhibitors presents another challenge. Traversing cell membrane is impeded due to the large molecular weight of peptide compounds, leading to restricted drug concentration in the body to reach minimum therapeutic levels [<xref rid="srt70207-bib-0029" ref-type="bibr">29</xref>, <xref rid="srt70207-bib-0030" ref-type="bibr">30</xref>]. Addressing this issue involves enhancing drug design; for instance, the drug bioavailability could be improved by incorporating suitable carriers or modifying groups. These challenges significantly limit the practical application of peptide tyrosinase inhibitors in clinical settings.</p></sec><sec id="srt70207-sec-0060"><label>2</label><title>Methods Introduction</title><sec id="srt70207-sec-0070"><label>2.1</label><title>Materials</title><p>Methyl thiazolyl tetrazolium (MTT) was procured from Sigma&#8208;Aldrich. DMEM/F12 Medium, fetal bovine serum (FBS), and penicillin/streptomycin were obtained from Gibco. Phosphate&#8208;buffered saline (PBS) was sourced from Solarbio, China. Analytical Grade Melanin, tranexamic acid, and L&#8208;DOPA were purchased from Sigma. Glabridin and kojic acid were acquired from Olibio Co. Ltd. and Yuanye Biotechnology Co. Ltd., respectively. All other reagents were obtained from commercial sources and used as received without further purification.</p></sec><sec id="srt70207-sec-0080"><label>2.2</label><title>Experiment</title><p>CHP&#8208;9 was synthesized using solid&#8208;phase peptide synthesis (SPPS), Scheme <xref rid="srt70207-fig-0007" ref-type="fig">1</xref>. The peptide sequence was assembled from Fmoc&#8208;protected amino acids (Fmoc&#8208;Gly&#8208;OH, Fmoc&#8208;Pro&#8208;OH, Fmoc&#8208;Gln(Trt)&#8208;OH) on a solid&#8208;phase resin reactor flask. After linear peptide assembly, the sequence was cyclized, deprotected, and purified via preparative reverse&#8208;phase C18 chromatography using methanol and water followed by lyophilization to obtain the pure compound (cyclopeptide <bold>CHP&#8208;9</bold>) Cyclo(Gln&#8208;Gly&#8208;Pro&#8208;Gln&#8208;Gly&#8208;Pro) (<bold>6</bold>), with a final purity of 99.2%, confirmed by HPLC analysis. HRMS (ESI&#8208;TOF): m/z [M + Na]<sup>+</sup> calcd for C<sub>24</sub>H<sub>36</sub>O<sub>8</sub>N<sub>8</sub>Na, 587.2554; found, 587.2549.</p><fig position="float" fig-type="SCHEME" id="srt70207-fig-0007" orientation="portrait"><label>SCHEME 1</label><caption><p>Synthetic strategy of cyclopeptide (<bold>CHP&#8208;9</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="SRT-31-e70207-g003.jpg"/></fig></sec><sec id="srt70207-sec-0090"><label>2.3</label><title>Cell Culture and Cytotoxicity Evaluations</title><p>Human melanocytes (Batch number: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MC210817">MC210817</ext-link>; Guangdong Biocell Biotechnology Co. Ltd.) were cultured in DMEM/F12 medium supplemented with 20% FBS (Hyclone) and 100&#160;U/mL penicillin at 37&#176;C with 5% CO<sub>2</sub> atmosphere.</p><p>For cytotoxicity, evaluation of peptides on human melanocyte cells was assessed using the standard MTT assay [<xref rid="srt70207-bib-0031" ref-type="bibr">31</xref>]. Cells were seeded in 96&#8208;well plates at a density of 10&#160;000 cells per well and incubated for 12&#160;h under standard culture conditions. After adherence, cells were treated with eight gradient concentrations of target peptides ranging from 0.0781 to 10&#160;mg/mL or a positive control (nonapeptide&#8208;1 and tranexamic acid alone or in combination 0.3% v/v) for 24&#160;h. A negative control group (culture medium containing 10% Dimethyl sulfoxide (DMSO), v/v) was included. Post&#8208;treatment, 0.5&#160;mg/mL MTT reagent was added to each well, followed by 4&#160;h of incubation at 37&#176;C. Formazan crystals formed in viable cells were dissolved in 150&#160;&#181;L DMSO, and absorbance was measured at 490&#160;nm using a Synergy multimode reader (BioTek, USA). Each concentration was tested in triplicate. Statistical significance was determined via one&#8208;way ANOVA (GraphPad Prism 5). All experiments were conducted in triplicate (<italic toggle="yes">n</italic> = 3).</p></sec><sec id="srt70207-sec-0100"><label>2.4</label><title>Determination of Melanin Content in Melanocyte</title><p>Upon reaching 80%&#8211;90% confluence, human melanocyte cells were dissolved with 0.25% trypsin to create a single&#8208;cell suspension. Then, the cells were seeded in 6&#8208;well plates at 200&#160;000 cells per well and cultured for 12&#160;h in a 37&#176;C humidified incubator (5% CO<sub>2</sub>, V/V). When the confluence of cells reached 40%&#8211;60%, they were incubated with specific peptides or the positive control for 24&#160;h. Following the incubation period, the supernatant was removed and the adherent cells were washed with PBS before being dispersed using trypsin (700 &#181;L/well, 0.25%). The dispersed cells were collected and centrifuged at 10&#160;000&#160;rpm for 10&#160;min. The cell pellet from each well was then treated with a mixture of distilled water (200 &#181;L), anhydrous ethanol (500 &#181;L), and ether (500 &#181;L). The mixture was vortexed and allowed to stand at room temperature for 20 min, followed by centrifugation at 3000&#160;rpm for 5 min. The precipitate was dissolved in 1 mL of 1 M NaOH containing 10% DMSO, then incubated at 80&#176;C in a water bath for 40 minutes. After incubation, the solution was transferred to a 96&#8208;well culture plate for optical density measurement at 405 nm. Each analysis was performed in triplicate and results were expressed as mean &#177; standard deviation (SD).</p></sec><sec id="srt70207-sec-0110"><label>2.5</label><title>Tyrosinase Inhibition Assay</title><p>The inhibition of tyrosinase activity was assessed according to the reported method [<xref rid="srt70207-bib-0032" ref-type="bibr">32</xref>]. The 6&#8208;well plates were incubated at 37&#176;C with human melanocyte cells at a density of 2.5&#215;10<sup>5</sup> cells per well in a humidified atmosphere (5% CO<sub>2</sub>) for 24&#160;h. Subsequently, these cells were exposed to glabridin (0.00625%, V/V) as the positive control, along with other tested compounds. Following treatment, cells were incubated at 37&#176;C for 24&#160;h using identical conditions. After treatment, cells in each well were rinsed with a PBS buffer solution (500 &#181;L) and lysed with a lysate buffer (100&#160;&#181;L containing 0.5% sodium deoxycholate) at approximately 0&#176;C for 1&#160;h. The resulting cell lysate was then centrifuged at 12&#160;000&#160;rpm at 4&#176;C for 20&#160;min. The protein concentration in the supernatant was quantified by a BCA Assay Kit (Beyotime Biotechnology, China). Samples were transferred to a 96&#8208;well plate in a total volume of 100&#160;&#181;L (90&#160;&#181;L of lysate supernatant and 20&#160;&#181;L of 0.1% L&#8208;DOPA) and incubated for 60&#160;min at 37&#176;C. The absorbance was measured at 475&#160;nm using a Synergy multimode reader (BioTek Corporation, USA).</p></sec><sec id="srt70207-sec-0120"><label>2.6</label><title>Molecular Docking</title><p>The cyclopeptide <bold>CHP&#8208;9</bold>, a potent inhibitor in tyrosinase inhibition assay, was docked into the active site cavity of human tyrosinase (PDB ID: 5M8M) using the MOE 2008 docking program after removing all water molecules from the crystal structure before the experiment to ensure precise docking results. The Protonate 3D application was added with hydrogens and partial charges. The docking site was defined for residues within an 8 &#197; radius of kojic acid. The initial 3D conformation of <bold>CHP&#8208;9</bold> was optimized in ChemBio3D Ultra using the MM2 energy minimization method. Default parameter values were applied for docking, with only the scoring function modified to ASE Scoring from the typical London dG. This scoring adjustment identified the best pose.</p><p>To assess the feasibility of the docking program for the ligand binding to human tyrosinase, we initially selected tyrosinase&#8208;related protein 1 in complex with kojic acid (PDB ID: 5M8M) and the docking structure of kojic acid was comparable to its crystallographic structure. This result implied that the MOE docking program is appropriate for identifying a binding model between CHP&#8208;9 and human tyrosinase.</p></sec></sec><sec id="srt70207-sec-0130"><label>3</label><title>Results and Discussion</title><sec id="srt70207-sec-0140"><label>3.1</label><title>Cytotoxicity Evaluation</title><p>The cytotoxicity of cyclopeptide <bold>CHP&#8208;9</bold> was assessed to determine its safety for cosmetic applications, along with tranexamic acid alone, tranexamic acid plus nonapeptide&#8208;1, and tranexamic acid combined with nonap3eptide&#8208;1 and cyclopeptide CHP&#8208;9, against human melanocyte cells.</p><p>As illustrated in Figure&#160;<xref rid="srt70207-fig-0001" ref-type="fig">1</xref>, tranexamic acid exhibited minimal cytotoxicity in human melanocytes at concentrations up to 2.5&#160;mg/mL, with cell viability remaining above 90% (Scheme&#160;<xref rid="srt70207-fig-0007" ref-type="fig">1</xref>). A slight reduction in cell viability was observed at higher concentrations (5 and 10&#160;mg/mL), but these effects were not statistically significant.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Growth inhibition of tranexamic acid against human melanocyte cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="SRT-31-e70207-g007.jpg"/></fig><p>Additionally, incubating cells with tranexamic acid and nonapeptide&#8208;1 at 0.3% (v/v) did not significantly affect cell viability (Figure&#160;<xref rid="srt70207-fig-0002" ref-type="fig">2</xref>). A slight decrease in cell viability was observed when the concentration of tranexamic acid was increased to 5&#160;mg/mL, but overall, no significant cytotoxic effects were detected.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Growth inhibition of tranexamic acid plus nonapeptide&#8208;1 (0.3%, v/v) against human melanocyte cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="SRT-31-e70207-g002.jpg"/></fig><p>For the group in which human melanocyte cells were treated with tranexamic acid (1&#160;mg/mL), nonapeptide&#8208;1 (0.3%, v/v), and cyclopeptide <bold>CHP&#8208;9</bold>, cell viability was evaluated using the MTT assay. As shown in Figure&#160;<xref rid="srt70207-fig-0003" ref-type="fig">3</xref>, even with <bold>CHP&#8208;9</bold> at a concentration of 2.5&#160;mg/mL, the mixture did not significantly affect cell growth, confirming that <bold>CHP&#8208;9</bold> does not introduce additional cytotoxicity to melanocytes.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Growth inhibition of tranexamic acid (1&#160;mg/mL), nonapeptide&#8208;1 (0.3%, V/V), and cyclopeptide (CHP&#8208;9) against human melanocyte cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="SRT-31-e70207-g001.jpg"/></fig><p>These findings suggest that <bold>CHP&#8208;9</bold> is a biocompatible tyrosinase inhibitor (noncytotoxic to human melanocytes at tested concentrations), unlike traditional skin&#8208;lightening agents such as hydroquinone, which exhibit cytotoxic effects at similar concentrations. These results support the safe application of <bold>CHP&#8208;9</bold> in cosmetic formulations.</p><p>CHP&#8208;9's low cytotoxicity may be attributed to its structural properties as a cyclic peptide. Cyclic peptides often demonstrate enhanced stability and selective bioactivity compared to linear counterparts, allowing them to interact specifically with target proteins (e.g., tyrosinase) while sparing nontarget cellular components. The lack of membrane&#8208;disruptive domains and the relatively small, hydrophilic nature of CHP&#8208;9 may limit off&#8208;target effects and cellular stress responses. Furthermore, its moderate binding affinity, as revealed through docking, suggests a balanced interaction that avoids nonspecific enzyme or receptor activation, thus minimizing cytotoxic outcomes.</p><p>The cytotoxicity assay results are critically relevant to assessing the practical potential of CHP&#8208;9 as a tyrosinase inhibitor. Many conventional tyrosinase inhibitors, such as hydroquinone, have shown efficacy but suffer from high cytotoxicity, limiting their safe use in cosmetic formulations. In contrast, CHP&#8208;9 maintained high cell viability (&gt;90%) across effective concentrations, indicating that its melanin&#8208;reducing and enzyme&#8208;inhibiting effects occur without compromising cell health. This suggests that CHP&#8208;9 can provide therapeutic efficacy with a favorable safety margin, making it a strong candidate for long&#8208;term application in skin&#8208;lightening products.</p></sec><sec id="srt70207-sec-0150"><label>3.2</label><title>Effect of Cyclopeptide on Intracellular Tyrosinase Activity and Melanin Content in Melanocyte Cells</title><p>The melanin&#8208;reducing effects of <bold>CHP&#8208;9</bold> and related compounds were investigated, as shown in Figure&#160;<xref rid="srt70207-fig-0004" ref-type="fig">4</xref>. The bar graph illustrates melanin content in human melanocyte cells following treatment with various compounds. The untreated control group displayed the highest melanin content (&#8764;30.90&#160;&#181;g/mL), which served as a baseline.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Inhibition of melanin production by cyclopeptide and related compounds (data shown are mean &#177; SD analyzed by one&#8208;way ANOVA with multiple comparison testing for the vehicle group and the indicated corresponding inhibition group. <italic toggle="yes">n</italic> = 3. *<italic toggle="yes">p</italic> &lt; 0.05 and **<italic toggle="yes">p</italic> &lt; 0.01 for comparison between the vehicle group and the indicated group; #<italic toggle="yes">p</italic> &lt; 0.05 for comparison between nonapeptide&#8208;1 and the indicated CHP&#8208;9 group).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="SRT-31-e70207-g005.jpg"/></fig><p>Treatment of human melanocytes with <bold>CHP&#8208;9</bold> (1%) alone significantly reduced melanin levels to &#8764;23.51&#160;&#181;g/mL, demonstrating its ability to inhibit melanin production effectively.</p><p>Tranexamic acid (2.5&#160;mg/mL) and nonapeptide&#8208;1 (0.3%, v/v) also exhibited melanin&#8208;reducing effects, though not as strongly as <bold>CHP&#8208;9</bold> alone. The combination of tranexamic acid and nonapeptide&#8208;1 resulted in a further decrease in melanin levels compared to their individual effects, suggesting a potential synergistic effect.</p><p>Additionally, glabridin (0.00625%, v/v), a well&#8208;known skin&#8208;lightening agent, was included in the study. It showed a strong inhibitory effect on melanin production, reinforcing its established role in tyrosinase inhibition.</p><p>Notably, the combination of tranexamic acid, nonapeptide&#8208;1, and <bold>CHP&#8208;9</bold> resulted in a significant reduction in melanin content, comparable to or even greater than the effects of individual compounds. This suggests that <bold>CHP&#8208;9</bold> enhances the skin&#8208;lightening potential of tranexamic acid and nonapeptide&#8208;1, making it a promising candidate for cosmetic applications targeting hyperpigmentation.</p><p>Figure&#160;<xref rid="srt70207-fig-0004" ref-type="fig">4</xref> demonstrates that <bold>CHP&#8208;9</bold> effectively reduces melanin production, both alone and in combination with other compounds. Its inhibitory effect is comparable to glabridin, a well&#8208;established skin&#8208;lightening agent. Overall, these findings suggest that CHP&#8208;9 is a safe and effective ingredient for cosmetic applications aimed at reducing hyperpigmentation.</p><p>The inhibitory effects of CHP&#8208;9 on melanin content may be attributed to its ability to bind specifically to the active site of tyrosinase, blocking its catalytic activity. This disruption in tyrosinase function prevents the conversion of L&#8208;DOPA to dopachrome, ultimately reducing melanin biosynthesis in melanocytes. Additionally, the stable structure of CHP&#8208;9 allows for sustained interaction with tyrosinase, leading to prolonged inhibitory effects. Its selective binding may also minimize interference with other intracellular signaling pathways, thereby reducing toxicity while effectively inhibiting melanin formation.</p></sec><sec id="srt70207-sec-0160"><label>3.3</label><title>Tyrosinase Inhibitory Activity Evaluation</title><p>The tyrosinase inhibitory activities of the tested compounds were evaluated according to previously reported methods [<xref rid="srt70207-bib-0025" ref-type="bibr">25</xref>] and the results are presented in Figure&#160;<xref rid="srt70207-fig-0005" ref-type="fig">5</xref>. Glabridin, a well&#8208;known tyrosinase inhibitor [<xref rid="srt70207-bib-0033" ref-type="bibr">33</xref>], was used as the positive control, demonstrating an inhibition rate of approximately 14% at a concentration of 0.00625% (v/v). Among the tested compounds, the cyclopeptide <bold>CHP&#8208;9</bold> (at 1% concentration) exhibited the highest tyrosinase inhibition, with a rate of 28.57%, which is about twice as potent as glabridin.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Tyrosinase inhibitory activity of synthetic peptides (data shown are mean &#177; SD analyzed by one&#8208;way ANOVA with multiple comparison testing for the vehicle group and tested groups. <italic toggle="yes">n</italic> = 3. *<italic toggle="yes">p</italic> &lt; 0.05 and **<italic toggle="yes">p</italic> &lt; 0.01 for comparison between the vehicle group and the indicated group).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="SRT-31-e70207-g006.jpg"/></fig><p>The inhibition rates of tranexamic acid (2.5&#160;mg/mL) and nonapeptide&#8208;1 (0.3% v/v) were measured at 10.71% and 16.67%, respectively, suggesting moderate tyrosinase inhibitory activity for both compounds. Notably, the combination of tranexamic acid and nonapeptide&#8208;1 showed a synergistic effect, achieving an inhibition rate of 29.76%, which is slightly higher than the sum of their individual inhibition rates (27.38%).</p><p>The highest inhibition rate (34.52%) was observed when <bold>CHP&#8208;9</bold> (1%) was combined with tranexamic acid (2.5&#160;mg/mL) and nonapeptide&#8208;1 (0.3% v/v), demonstrating the most potent inhibitory efficacy among all tested groups.</p><p>The statistical significance of the results was analyzed using one&#8208;way ANOVA with multiple comparison testing. The differences in inhibition rates between the vehicle control and tested groups were statistically significant (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">p</italic> &lt; 0.01), as indicated in Figure&#160;<xref rid="srt70207-fig-0005" ref-type="fig">5</xref>. The observed differences suggest that <bold>CHP&#8208;9</bold>, both alone and in combination with other compounds, effectively inhibits tyrosinase activity, further supporting its potential application in cosmetic formulations.</p><p>These results suggest that <bold>CHP&#8208;9</bold> is a highly effective tyrosinase inhibitor, exhibiting significantly stronger activity compared to the standard positive control, glabridin. The synergistic enhancement observed in the tranexamic acid and nonapeptide&#8208;1 combination indicates that their combined effect is greater than the sum of their individual inhibition rates, likely due to complementary mechanisms of tyrosinase inhibition.</p><p>Moreover, the tri&#8208;combination of <bold>CHP&#8208;9</bold>, tranexamic acid, and nonapeptide&#8208;1 displayed the most potent inhibitory activity, suggesting that multitarget approaches may be more effective in tyrosinase inhibition. This combination may exert its effects through different inhibition pathways, leading to a higher overall suppression of tyrosinase activity.</p><p>These findings highlight the potential application of <bold>CHP&#8208;9</bold>, alone or in combination with other agents, in skin&#8208;lightening and hyperpigmentation treatments. Further studies will be necessary to elucidate the precise mechanism underlying these synergistic effects and to assess their in vivo efficacy.</p></sec><sec id="srt70207-sec-0170"><label>3.4</label><title>Molecular Docking Between the Cyclopeptide and Tyrosinase</title><p>Recently, computer&#8208;based simulation, known as molecular docking, has become widely used to investigate potential interaction mechanisms between inhibitors and corresponding targets. To gain insights into the molecular determinants modulating the inhibitory activity of the cyclopeptide <bold>CHP&#8208;9</bold> against tyrosinase, we perform molecular docking studies of <bold>CHP&#8208;9</bold> with human tyrosinase using the MOE 2008 software based on the x&#8208;ray crystal structure of human tyrosinase&#8208;related protein 1 in complex with kojic acid in the active site cavity (PDB ID: 5M8M).</p><p>As shown in Figure&#160;<xref rid="srt70207-fig-0006" ref-type="fig">6</xref>, the cyclopeptide <bold>CHP&#8208;9</bold> is bound within the binding cavity, positioned above the surface of the catalytic center. Different interaction types can significantly influence the structure binding affinity and stability between the tyrosinase and <bold>CHP&#8208;9</bold> peptide. Specifically, a total of six hydrogen bonds were formed (one cation hydrogen bond and five conventional hydrogen bonds) between peptide <bold>CHP&#8208;9</bold> and tyrosinase, including six amino acid residues in tyrosinase, that is, Asp212, Tyr362, His321, Gly389, Arg374, and His382.</p><fig position="float" fig-type="FIGURE" id="srt70207-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>The molecular docking simulation results of the cyclopeptide <bold>CHP&#8208;9</bold> at the active site of tyrosinase (2D&#8208;interactions).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="SRT-31-e70207-g004.jpg"/></fig><p>Additionally, the hydrophobic aliphatic residue leucine382 plays a pivotal role in tyrosinase inhibition by directly interacting with tyrosinase to block dopaquinone formation. Considering the results from molecular docking, cyclopeptide <bold>CHP&#8208;9</bold> acts as a tyrosinase inhibitory peptide, and we observed that hydrogen bonding was crucial in influencing the binding affinities and structure stabilities of the peptide&#8211;tyrosinase complexes, thereby blocking the tyrosinase activity.</p></sec></sec><sec id="srt70207-sec-0180"><label>4</label><title>Conclusion</title><p>Melanin content is a key determinant of skin pigmentation, and inhibiting melanin formation is a crucial strategy for achieving skin&#8208;lightening effects. In this study, we identified CHP&#8208;9, a novel cyclopeptide, as a potent and safe human tyrosinase inhibitor. CHP&#8208;9 demonstrated significant tyrosinase inhibition, with an inhibition rate of 28.57% at 1% concentration. Furthermore, in the melanin formation assay, exposure to <bold>CHP&#8208;9</bold> alone led to a reduction in cellular melanin content from 30.90 &#177; 1.13 to 23.51 &#177; 1.14&#160;&#181;g/mL, indicating its ability to effectively suppress melanin biosynthesis. Molecular docking studies further confirmed the strong binding affinity of <bold>CHP&#8208;9</bold> to tyrosinase, primarily facilitated by hydrogen bonding interactions.</p><p>Despite these promising results, some limitations and challenges remain. Although <bold>CHP&#8208;9</bold> has shown strong in vitro tyrosinase inhibitory activity, further in vivo studies are required to evaluate its efficacy, bioavailability, and long&#8208;term safety in skin applications. Additionally, optimizing the formulation and delivery system of <bold>CHP&#8208;9</bold> in cosmetic products is essential to enhance its stability and penetration into the skin. Future research should also explore structure&#8211;activity relationship (SAR) studies to improve its inhibitory potency and selectivity.</p><p>Overall, these findings suggest that <bold>CHP&#8208;9</bold> holds great potential as a bioactive compound for skin&#8208;lightening applications in cosmetics. However, further investigation is necessary to overcome existing challenges and fully realize its therapeutic and commercial potential.</p></sec><sec id="srt70207-sec-0200"><title>Ethics Statement</title><p>Ethical review and approval were not required for this study as it did not involve humans or animals.</p></sec><sec sec-type="COI-statement" id="srt70207-sec-0210"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="srt70207-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="srt70207-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Scheme 1</bold>: Deprotection of Glycine</p><p>
<bold>Scheme 2</bold>: deprotection of Proline</p><p>
<bold>Scheme 3</bold>: Synthesis of linear peptide:</p><p>
<bold>Scheme 4</bold>: cleavage of the linear peptide from resin.</p><p>
<bold>Scheme 5</bold>: Cyclization of linear peptide:</p><p>
<bold>Scheme 6</bold>: Deprotection of cyclized peptide</p><p>
<bold>Table S1</bold>: 1H&#8208;NMR Data (D2O, 600 MHz) of Compound CHP&#8208;9 (&#948; in ppm and J in Hz)</p><p>
<bold>Table SII</bold>: 13C&#8208;NMR Data (D2O, 600 MHz) of Compound CHP&#8208;9 (&#948; in ppm and J in Hz)</p><p>See Supplementary Material (Table <xref rid="srt70207-supinfo-0001" ref-type="">S1</xref> and Table <xref rid="srt70207-supinfo-0001" ref-type="">S2</xref>) for detailed NMR data of compound CHP&#8208;9.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="SRT-31-e70207-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="srt70207-sec-0190"><title>Acknowledgments</title><p>This work was supported by the National Natural Science Foundation of China (NSFC; Grant 81673281).</p></ack><sec sec-type="data-availability" id="srt70207-sec-0230"><title>Data Availability Statement</title><p>The synthesis and characterization data supporting the findings of this study are provided in the Supporting Information, along with a preprint publicly accessible at [DOI: 10.20944/preprints202410.1006.v1]. Any additional data required will be available from the corresponding authors upon reasonable request.</p></sec><ref-list id="srt70207-bibl-0001"><title>References</title><ref id="srt70207-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="srt70207-cite-0001"><string-name name-style="western"><given-names>M.</given-names><surname>Saeedi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Morteza&#8208;Semnani</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Akbari</surname></string-name>, et&#160;al., &#8220;<article-title>Eco&#8208;Friendly Preparation, Characterization, Evaluation of Anti&#8208;Melanogenesis/Antioxidant Effect and In Vitro/In Vivo Safety Profile of Kojic Acid Loaded Niosome as Skin Lightener Preparation</article-title>,&#8221; <source>Journal of Biomaterials Science</source><volume>34</volume>, no. <issue>14</issue> (<year>2023</year>): <fpage>1952</fpage>&#8211;<lpage>1980</lpage>. Polymer edition.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09205063.2023.2201817</pub-id><pub-id pub-id-type="pmid">37036014</pub-id></mixed-citation></ref><ref id="srt70207-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="srt70207-cite-0002"><string-name name-style="western"><given-names>M.</given-names><surname>Saeedi</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Rezanejad Gatabi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Morteza&#8208;Semnani</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Rahimnia</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Yazdian&#8208;Robati</surname></string-name>, and <string-name name-style="western"><given-names>S. M. H.</given-names><surname>Hashemi</surname></string-name>, &#8220;<article-title>Preparation of Arbutin Hydrogel Formulation as Green Skin Lightener Formulation: In Vitro and In Vivo Evaluation</article-title>,&#8221; <source>Journal of Dispersion Science and Technology</source> (<year>2024</year>): <fpage>1</fpage>&#8211;<lpage>13</lpage>, <pub-id pub-id-type="doi">10.1080/01932691.2024.2371954</pub-id>.</mixed-citation></ref><ref id="srt70207-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="srt70207-cite-0003"><string-name name-style="western"><given-names>Z. R.</given-names><surname>Gatabi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Saeedi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Morteza&#8208;Semnani</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Rahimnia</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Yazdian&#8208;Robati</surname></string-name>, and <string-name name-style="western"><given-names>S. M. H.</given-names><surname>Hashemi</surname></string-name>, &#8220;<article-title>Green Preparation, Characterization, Evaluation of Anti&#8208;Melanogenesis Effect and In Vitro/In Vivo Safety Profile of Kojic Acid Hydrogel as Skin Lightener Formulation</article-title>,&#8221; <source>Journal of Biomaterials Science</source><volume>33</volume>, no. <issue>17</issue> (<year>2022</year>): <fpage>2270</fpage>&#8211;<lpage>2291</lpage>. Polymer Edition.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09205063.2022.2103624</pub-id><pub-id pub-id-type="pmid">35856432</pub-id></mixed-citation></ref><ref id="srt70207-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="srt70207-cite-0004"><string-name name-style="western"><given-names>S.</given-names><surname>Zolghadri</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bahrami</surname></string-name>, <string-name name-style="western"><given-names>M. T.</given-names><surname>Hassan Khan</surname></string-name>, et&#160;al., &#8220;<article-title>A Comprehensive Review on Tyrosinase Inhibitors</article-title>,&#8221; <source>Journal of Enzyme Inhibition and Medicinal Chemistry</source><volume>34</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>279</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="pmid">30734608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14756366.2018.1545767</pub-id><pub-id pub-id-type="pmcid">PMC6327992</pub-id></mixed-citation></ref><ref id="srt70207-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="srt70207-cite-0005"><string-name name-style="western"><given-names>Y.</given-names><surname>Qi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Polyphenol Oxidase Plays a Critical Role in Melanin Formation in the Fruit Skin of Persimmon (Diospyros kaki cv. &#8216;Heishi&#8217;)</article-title>,&#8221; <source>Food Chemistry</source><volume>330</volume> (<year>2020</year>): <elocation-id>127253</elocation-id>.<pub-id pub-id-type="pmid">32534157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.foodchem.2020.127253</pub-id></mixed-citation></ref><ref id="srt70207-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="srt70207-cite-0006"><string-name name-style="western"><given-names>X.</given-names><surname>Lai</surname></string-name>, <string-name name-style="western"><given-names>H. J.</given-names><surname>Wichers</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Soler&#8208;Lopez</surname></string-name>, and <string-name name-style="western"><given-names>B. W.</given-names><surname>Dijkstra</surname></string-name>, &#8220;<article-title>Structure and Function of Human Tyrosinase and Tyrosinase&#8208;Related Proteins</article-title>,&#8221; <source>Chemistry: A European Journal</source><volume>24</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>47</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">29052256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201704410</pub-id></mixed-citation></ref><ref id="srt70207-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="srt70207-cite-0007"><string-name name-style="western"><given-names>&#193;.</given-names><surname>S&#225;nchez&#8208;Ferrer</surname></string-name>, <string-name name-style="western"><given-names>J. N.</given-names><surname>Rodr&#237;guez&#8208;L&#243;pez</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Garc&#237;a&#8208;C&#225;novas</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Garc&#237;a&#8208;Carmona</surname></string-name>, &#8220;<article-title>Tyrosinase: A Comprehensive Review of Its Mechanism</article-title>,&#8221; <source>Biochimica et Biophysica Acta</source><volume>1247</volume>, no. <issue>1</issue> (<year>1995</year>): <fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">7873577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0167-4838(94)00204-t</pub-id></mixed-citation></ref><ref id="srt70207-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="srt70207-cite-0008"><string-name name-style="western"><given-names>S.</given-names><surname>Ito</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sugumaran</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Wakamatsu</surname></string-name>, &#8220;<article-title>Chemical Reactivities of Ortho&#8208;Quinones Produced in Living Organisms: Fate of Quinonoid Products Formed by Tyrosinase and Phenoloxidase Action on Phenols and Catechols</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>21</volume> (<year>2020</year>): <fpage>6080</fpage>, <pub-id pub-id-type="doi">10.3390/ijms21176080</pub-id>.<pub-id pub-id-type="pmid">32846902</pub-id><pub-id pub-id-type="pmcid">PMC7504153</pub-id></mixed-citation></ref><ref id="srt70207-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="srt70207-cite-0009"><string-name name-style="western"><given-names>K. U.</given-names><surname>Zaidi</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Ali</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ali</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Naaz</surname></string-name>, &#8220;<article-title>Natural Tyrosinase Inhibitors: Role of Herbals in the Treatment of Hyperpigmentary Disorders</article-title>,&#8221; <source>Mini&#8208;Reviews in Medicinal Chemistry</source><volume>19</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>796</fpage>&#8211;<lpage>808</lpage>.<pub-id pub-id-type="pmid">31244414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389557519666190116101039</pub-id></mixed-citation></ref><ref id="srt70207-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="srt70207-cite-0010"><string-name name-style="western"><given-names>S.</given-names><surname>Zolghadri</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Beygi</surname></string-name>, <string-name name-style="western"><given-names>T. F.</given-names><surname>Mohammad</surname></string-name>, et&#160;al., &#8220;<article-title>Targeting Tyrosinase in Hyperpigmentation: Current Status, Limitations and Future Promises</article-title>,&#8221; <source>Biochemical Pharmacology</source><volume>212</volume> (<year>2023</year>): <elocation-id>115574</elocation-id>.<pub-id pub-id-type="pmid">37127249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115574</pub-id></mixed-citation></ref><ref id="srt70207-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="srt70207-cite-0011"><string-name name-style="western"><given-names>W.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Stehbens</surname></string-name>, <string-name name-style="western"><given-names>R. T.</given-names><surname>Barnard</surname></string-name>, <string-name name-style="western"><given-names>M. A. T.</given-names><surname>Blaskovich</surname></string-name>, and <string-name name-style="western"><given-names>Z. M.</given-names><surname>Ziora</surname></string-name>, &#8220;<article-title>Dysregulation of Tyrosinase Activity: A Potential Link Between Skin Disorders and Neurodegeneration</article-title>,&#8221; <source>Journal of Pharmacy and Pharmacology</source><volume>76</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>13</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">38007394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpp/rgad107</pub-id></mixed-citation></ref><ref id="srt70207-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="srt70207-cite-0012"><string-name name-style="western"><given-names>I.</given-names><surname>Carballo&#8208;Carbajal</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Laguna</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Romero&#8208;Gim&#233;nez</surname></string-name>, et&#160;al., &#8220;<article-title>Brain Tyrosinase Overexpression Implicates Age&#8208;Dependent Neuromelanin Production in Parkinson's Disease Pathogenesis</article-title>,&#8221; <source>Nature Communications</source><volume>10</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>973</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-08858-y</pub-id><pub-id pub-id-type="pmcid">PMC6405777</pub-id><pub-id pub-id-type="pmid">30846695</pub-id></mixed-citation></ref><ref id="srt70207-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="srt70207-cite-0013"><string-name name-style="western"><given-names>T.</given-names><surname>Chang</surname></string-name>, &#8220;<article-title>An Updated Review of Tyrosinase Inhibitors</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>10</volume> (<year>2009</year>): <fpage>2440</fpage>&#8211;<lpage>2475</lpage>, <pub-id pub-id-type="doi">10.3390/ijms10062440</pub-id>.<pub-id pub-id-type="pmid">19582213</pub-id><pub-id pub-id-type="pmcid">PMC2705500</pub-id></mixed-citation></ref><ref id="srt70207-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="srt70207-cite-0014"><string-name name-style="western"><given-names>X.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Dai</surname></string-name>, et&#160;al., &#8220;<article-title>Encapsulation Artocarpanone and Ascorbic Acid in O/W Microemulsions: Preparation, Characterization, and Antibrowning Effects in Apple Juice</article-title>,&#8221; <source>Food Chemistry</source><volume>192</volume> (<year>2016</year>): <fpage>1033</fpage>&#8211;<lpage>1040</lpage>.<pub-id pub-id-type="pmid">26304444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.foodchem.2015.07.124</pub-id></mixed-citation></ref><ref id="srt70207-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="srt70207-cite-0015"><string-name name-style="western"><given-names>J.</given-names><surname>Ros</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rodr&#237;guez&#8208;L&#243;pez</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Garc&#237;a&#8208;C&#225;novas</surname></string-name>, &#8220;<article-title>Effect of L&#8208;ascorbic Acid on the Monophenolase Activity of Tyrosinase</article-title>,&#8221; <source>Biochemical Journal</source><volume>295</volume>, no. <issue>1</issue> (<year>1993</year>): <fpage>309</fpage>&#8211;<lpage>312</lpage>.<pub-id pub-id-type="pmid">8216233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/bj2950309</pub-id><pub-id pub-id-type="pmcid">PMC1134854</pub-id></mixed-citation></ref><ref id="srt70207-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="srt70207-cite-0016"><string-name name-style="western"><given-names>Y.</given-names><surname>Wen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Chai</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Yu</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Effect of Ascorbic Acid on Tyrosinase and Its Anti&#8208;Browning Activity in Fresh&#8208;Cut Fuji Apple</article-title>,&#8221; <source>Journal of Food Biochemistry</source><volume>45</volume>, no. <issue>12</issue> (<year>2021</year>): <elocation-id>e13995</elocation-id>.<pub-id pub-id-type="pmid">34730855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jfbc.13995</pub-id></mixed-citation></ref><ref id="srt70207-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="srt70207-cite-0017"><string-name name-style="western"><given-names>J.</given-names><surname>Cabanes</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chazarra</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Garcia&#8208;Carmona</surname></string-name>, &#8220;<article-title>Kojic Acid, a Cosmetic Skin Whitening Agent, Is a Slow&#8208;binding Inhibitor of Catecholase Activity of Tyrosinase</article-title>,&#8221; <source>Journal of Pharmacy and Pharmacology</source><volume>46</volume>, no. <issue>12</issue> (<year>1994</year>): <fpage>982</fpage>&#8211;<lpage>985</lpage>.<pub-id pub-id-type="pmid">7714722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.2042-7158.1994.tb03253.x</pub-id></mixed-citation></ref><ref id="srt70207-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="srt70207-cite-0018"><string-name name-style="western"><given-names>Y. H.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Jeon</surname></string-name>, and <string-name name-style="western"><given-names>J.&#8208;H.</given-names><surname>Mah</surname></string-name>, &#8220;<article-title>Tyrosinase Inhibitory Activity of Soybeans Fermented With <italic toggle="yes">Bacillus subtilis</italic> Capable of Producing a Phenolic Glycoside, Arbutin</article-title>,&#8221; <source>Antioxidants (Basel)</source><volume>9</volume>, no. <issue>12</issue> (<year>2020</year>): <fpage>1301</fpage>, <pub-id pub-id-type="doi">10.3390/antiox9121301</pub-id>.<pub-id pub-id-type="pmid">33353058</pub-id><pub-id pub-id-type="pmcid">PMC7766266</pub-id></mixed-citation></ref><ref id="srt70207-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="srt70207-cite-0019"><string-name name-style="western"><given-names>P.</given-names><surname>Rudeekulthamrong</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Kaulpiboon</surname></string-name>, &#8220;<article-title>Optimization of Amylomaltase for the Synthesis of &#945;&#8208;Arbutin Derivatives as Tyrosinase Inhibitors</article-title>,&#8221; <source>Carbohydrate Research</source><volume>494</volume> (<year>2020</year>): <elocation-id>108078</elocation-id>.<pub-id pub-id-type="pmid">32622087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2020.108078</pub-id></mixed-citation></ref><ref id="srt70207-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="srt70207-cite-0020"><string-name name-style="western"><given-names>A.</given-names><surname>Palumbo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>d'Ischia</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Misuraca</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Prota</surname></string-name>, &#8220;<article-title>Mechanism of Inhibition of Melanogenesis by Hydroquinone</article-title>,&#8221; <source>Biochimica et Biophysica Acta: General Subjects</source><volume>1073</volume>, no. <issue>1</issue> (<year>1991</year>): <fpage>85</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-4165(91)90186-k</pub-id><pub-id pub-id-type="pmid">1899343</pub-id></mixed-citation></ref><ref id="srt70207-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="srt70207-cite-0021"><string-name name-style="western"><given-names>T.</given-names><surname>Mann</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Gerwat</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Batzer</surname></string-name>, et&#160;al., &#8220;<article-title>Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different From Mushroom Tyrosinase</article-title>,&#8221; <source>Journal of Investigative Dermatology</source><volume>138</volume>, no. <issue>7</issue> (<year>2018</year>): <fpage>1601</fpage>&#8211;<lpage>1608</lpage>.<pub-id pub-id-type="pmid">29427586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2018.01.019</pub-id></mixed-citation></ref><ref id="srt70207-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="srt70207-cite-0022"><string-name name-style="western"><given-names>S.</given-names><surname>Ullah</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Son</surname></string-name>, <string-name name-style="western"><given-names>H. Y.</given-names><surname>Yun</surname></string-name>, <string-name name-style="western"><given-names>D. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Chun</surname></string-name>, and <string-name name-style="western"><given-names>H. R.</given-names><surname>Moon</surname></string-name>, &#8220;<article-title>Tyrosinase Inhibitors: A Patent Review (2011&#8208;2015)</article-title>,&#8221; <source>Expert Opinion on Therapeutic Patents</source><volume>26</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>347</fpage>&#8211;<lpage>362</lpage>.<pub-id pub-id-type="pmid">26815044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543776.2016.1146253</pub-id></mixed-citation></ref><ref id="srt70207-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="srt70207-cite-0023"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Recent Advances in the Design and Discovery of Synthetic Tyrosinase Inhibitors</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>224</volume> (<year>2021</year>): <elocation-id>113744</elocation-id>.<pub-id pub-id-type="pmid">34365131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113744</pub-id></mixed-citation></ref><ref id="srt70207-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="srt70207-cite-0024"><string-name name-style="western"><given-names>Q.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fan</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Duan</surname></string-name>, &#8220;<article-title>Five Individual Polyphenols as Tyrosinase Inhibitors: Inhibitory Activity, Synergistic Effect, Action Mechanism, and Molecular Docking</article-title>,&#8221; <source>Food Chemistry</source><volume>297</volume> (<year>2019</year>): <elocation-id>124910</elocation-id>.<pub-id pub-id-type="pmid">31253292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.foodchem.2019.05.184</pub-id></mixed-citation></ref><ref id="srt70207-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="srt70207-cite-0025"><string-name name-style="western"><given-names>M.</given-names><surname>Schurink</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>van Berkel</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wichers</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Boeriu</surname></string-name>, &#8220;<article-title>Novel Peptides With Tyrosinase Inhibitory Activity</article-title>,&#8221; <source>Peptides</source><volume>28</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>485</fpage>&#8211;<lpage>495</lpage>.<pub-id pub-id-type="pmid">17241698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.peptides.2006.11.023</pub-id></mixed-citation></ref><ref id="srt70207-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="srt70207-cite-0026"><string-name name-style="western"><given-names>P.</given-names><surname>Yap</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Gan</surname></string-name>, &#8220;<article-title>Tyrosinase Inhibitory Peptides: Structure&#8208;Activity Relationship Study on Peptide Chemical Properties, Terminal Preferences and Intracellular Regulation of Melanogenesis Signaling Pathways</article-title>,&#8221; <source>Biochimica et Biophysica Acta: General Subjects</source><volume>1868</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>130503</elocation-id>.<pub-id pub-id-type="pmid">37923180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbagen.2023.130503</pub-id></mixed-citation></ref><ref id="srt70207-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="srt70207-cite-0027"><string-name name-style="western"><given-names>T.</given-names><surname>Pillaiyar</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Manickam</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Namasivayam</surname></string-name>, &#8220;<article-title>Skin Whitening Agents: Medicinal Chemistry Perspective of Tyrosinase Inhibitors</article-title>,&#8221; <source>Journal of Enzyme Inhibition and Medicinal Chemistry</source><volume>32</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>403</fpage>&#8211;<lpage>425</lpage>.<pub-id pub-id-type="pmid">28097901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14756366.2016.1256882</pub-id><pub-id pub-id-type="pmcid">PMC6010116</pub-id></mixed-citation></ref><ref id="srt70207-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="srt70207-cite-0028"><string-name name-style="western"><given-names>Y.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zeng</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Hu</surname></string-name>, &#8220;<article-title>The Hypopigmentation Mechanism of Tyrosinase Inhibitory Peptides Derived From Food Proteins: An Overview</article-title>,&#8221; <source>Molecules (Basel, Switzerland)</source><volume>27</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>2710</fpage>.<pub-id pub-id-type="pmid">35566061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27092710</pub-id><pub-id pub-id-type="pmcid">PMC9103514</pub-id></mixed-citation></ref><ref id="srt70207-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="srt70207-cite-0029"><string-name name-style="western"><given-names>W.</given-names><surname>Xue</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhao</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Yu</surname></string-name>, &#8220;<article-title>Identification and Molecular Mechanism of Novel Tyrosinase Inhibitory Peptides From Collagen</article-title>,&#8221; <source>Journal of Food Science</source><volume>87</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>2744</fpage>&#8211;<lpage>2756</lpage>.<pub-id pub-id-type="pmid">35603815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1750-3841.16160</pub-id></mixed-citation></ref><ref id="srt70207-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="srt70207-cite-0030"><string-name name-style="western"><given-names>J.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Haider</surname></string-name>, et&#160;al., &#8220;<article-title>Improved Efficacy of Linear Glutathione&#8208;Peptide Chaperon Complexes on Melanogenesis Inhibition and Transdermal Delivery</article-title>,&#8221; <source>Bioorganic Chemistry</source><volume>152</volume> (<year>2024</year>): <elocation-id>107719</elocation-id>.<pub-id pub-id-type="pmid">39173226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2024.107719</pub-id></mixed-citation></ref><ref id="srt70207-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="srt70207-cite-0031"><string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, et&#160;al., &#8220;<article-title>Anti&#8208;Cancer Activity of Synthesized 5&#8208;Benzyl Juglone on Selected Human Cancer Cell Lines</article-title>,&#8221; <source>Anti&#8208;Cancer Agents in Medicinal Chemistry</source><volume>24</volume>, no. <issue>11</issue> (<year>2024</year>): <fpage>845</fpage>&#8211;<lpage>852</lpage>.<pub-id pub-id-type="pmid">36165520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520622666220926110858</pub-id></mixed-citation></ref><ref id="srt70207-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="srt70207-cite-0032"><string-name name-style="western"><given-names>S.</given-names><surname>Ullah</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Park</surname></string-name>, et&#160;al., &#8220;<article-title>Antioxidant, Anti&#8208;Tyrosinase and Anti&#8208;Melanogenic Effects of (E)&#8208;2,3&#8208;diphenylacrylic Acid Derivatives</article-title>,&#8221; <source>Bioorganic &amp; Medicinal Chemistry</source><volume>27</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>2192</fpage>&#8211;<lpage>2200</lpage>.<pub-id pub-id-type="pmid">31027707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2019.04.020</pub-id></mixed-citation></ref><ref id="srt70207-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="srt70207-cite-0033"><string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Huang</surname></string-name>, &#8220;<article-title>Inhibitory Mechanisms of Glabridin on Tyrosinase</article-title>,&#8221; <source>Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy</source><volume>168</volume> (<year>2016</year>): <fpage>111</fpage>&#8211;<lpage>117</lpage>.<pub-id pub-id-type="pmid">27288962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.saa.2016.06.008</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>